(Reuters) – Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
